Kyongtae Ty Bae

Kyongtae Ty Bae

Auto-generated profile, based on publicly available information

Kyongtae Ty Bae

Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Radiology
Verified
Journal Article
Closed access
KBKyongtae T. Bae
Kyongtae T. Bae
The continuing advances in computed tomographic (CT) technology in the past decades have provided ongoing opportunities to improve CT image quality and clinical practice and discover new clinical CT imaging applications. New CT technology, however, has introduced new challenges in clinical radiology practice. One of the challenges is with intravenous contrast medium administration and scan timing. In this article, contrast medium pharmacokinetics and patient, contrast medium, and CT scanning factors associated with contrast enhancement and scan timing are presented and discussed. Published data from clinical studies of contrast medium and physiology are reviewed and interpreted. Computer simulation data are analyzed to provide an in-depth analysis of various factors associated with contrast enhancement and scan timing. On the basis of basic principles and analysis of the factors, clinical considerations and modifications to protocol design that are necessary to optimize contrast enhancement for common clinical CT applications are proposed.

1 March 2008 in American Journal of Roentgenology
Verified
Journal Article
Closed access
KBKyongtae T. Bae
Kyongtae T. Bae
BSBrian A. Seeck
Brian A. Seeck
CHCharles F. Hildebolt
Charles F. Hildebolt
CTCheng Tao
Cheng Tao
FZFang Zhu
Fang Zhu
PWPamela K. Woodard
Pamela K. Woodard
OBJECTIVE. The purpose of our study was to evaluate the effect of body weight, height, body surface area (BSA), body mass index (BMI), and obesity on aortic contrast enhancement in cardiac MDCT.MATERIALS AND METHODS. Seventy-three consecutive patients underwent cardiac CT angiography on a 64-MDCT scanner. Seventy-five mL of contrast medium (350 mg I/mL) was injected at 4.5 mL/s, followed by a 40-mL saline flush at 4.5 mL/s. The scanning delay of CT was determined with a bolus tracking technique. Aortic attenuation was measured over the aortic-root lumen. BMI and BSA were calculated from the patient's body weight and height. The patients were divided into low-(BMI < 30) and high-(≥ 30) BMI groups. Associations of aortic attenuation with body weight, height, BMI, and BSA were evaluated with regression analysis and the Student's t test.RESULTS. Strong inverse correlations were seen between aortic attenuation and body weight (r = –0.73), height (r = –0.47), BMI (r = –0.63), and BSA (r = –0.74) (p < 0.001 for ...

1 October 2012 in Radiology
Verified
Journal Article
Closed access
AFAlessandro Furlan
Alessandro Furlan
AAAyaz Aghayev
Ayaz Aghayev
CCChung-Chou H. Chang
Chung-Chou H. Chang
APAmol Patil
Amol Patil
KJKyung Nyeo Jeon
Kyung Nyeo Jeon
KBKyongtae T. Bae
Kyongtae T. Bae
In patients with acute pulmonary embolism, right heart dilatation was associated with higher risk of short-term mortality along with history of congestive heart failure and cancer. PurposeTo assess the correlation between volumetric measurements of clot, semiquantitative clot burden indexes, and signs of right heart dysfunction at computed tomographic (CT) pulmonary angiograp...

1 February 2007 in Radiology
Verified
Journal Article
Closed access
KBKyongtae T. Bae
Kyongtae T. Bae
CTCheng Tao
Cheng Tao
SGSafiye Gürel
Safiye Gürel
CHCheng Hong
Cheng Hong
FZFang Zhu
Fang Zhu
CHCharles F. Hildebolt
Charles F. Hildebolt
To retrospectively evaluate the amount of contrast medium required with 16- and 64-section computed tomography (CT) for a given patient weight to achieve desirable contrast enhancement during pulmonary CT angiography. Institutional review board approval was obtained, and informed consent was not required for this HIPAA-compliant study. Eighty-five patients (35 men, 50 women; range, 22-87 years) who had undergone 16-section (n = 48) or 64-section (n = 37) CT for the detection of pulmonary embolism were retrospectively evaluated. Contrast medium containing 350 mg of iodine per milliliter was injected at a rate of 4 mL/sec. The injected volume corresponded to the injection rate multiplied by the sum of the scanning delay plus the scanning duration, up to 125 mL. The scanning delay was determined with bolus tracking. Contrast enhancement was measured in the main pulmonary artery and the aorta. For each patient, the injected contrast medium volume per body weight index was calculated. Linear regression analysis was performed, and the Wilcoxon signed rank test was used to assess differences between 16- and 64-section CT. A range of patient weights (45.3-153.0 kg) and contrast medium volumes (76-125 mL) were noted. The regression formula indicated that 1.2 mL per kilogram body weight of contrast medium was required to achieve 250 HU. The median scanning duration was shorter for 64-section CT than for 16-section CT (5.7 seconds vs 9.5 seconds, P < .001). Consequently, 64-section CT required 17.6% less contrast medium than did 16-section CT (85.4 mL vs 103.6 mL, P < .001). Median contrast enhancement in the pulmonary artery was 8.9% lower with 64-section CT than with 16-section CT (257.7 HU vs 282.9 HU, P = .11). To achieve consistent contrast enhancement during pulmonary CT angiography, the amount of contrast medium can be adjusted to the patient's body weight.

6 August 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
SLSravanthi Lavu
Sravanthi Lavu
LVLisa E. Vaughan
Lisa E. Vaughan
SSSarah R. Senum
Sarah R. Senum
TKTimothy L. Kline
Timothy L. Kline
ACArlene B. Chapman
Arlene B. Chapman
PHPeter C. Harris
Peter C. Harris
BACKGROUND: A treatment option for autosomal dominant polycystic kidney disease (ADPKD) has highlighted the need to identify rapidly progressive patients. Kidney size/age and genotype have predictive power for renal outcomes, but their relative and additive value, plus associated trajectories of disease progression, are not well defined. METHODS: The value of genotypic and/or kidney imaging data (Mayo Imaging Class; MIC) to predict the time to functional (end-stage kidney disease [ESKD] or decline in estimated glomerular filtration rate [eGFR]) or structural (increase in height-adjusted total kidney volume [htTKV]) outcomes were evaluated in a Mayo Clinic PKD1/PKD2 population, and eGFR and htTKV trajectories from 20–65 years of age were modeled and independently validated in similarly defined CRISP and HALT PKD patients. RESULTS: Both genotypic and imaging groups strongly predicted ESKD and eGFR endpoints, with genotype improving the imaging predictions and vice versa; a multivariate model had strong discriminatory power (C-index = 0.845). However, imaging but not genotypic groups predicted htTKV growth, although more severe genotypic and imaging groups had larger kidneys at a young age. The trajectory of eGFR decline was linear from baseline in the most severe genotypic and imaging groups, but it was curvilinear in milder groups. Imaging class trajectories differentiated htTKV growth rates; severe classes had rapid early growth and large kidneys, but growth later slowed. CONCLUSION: The value of imaging, genotypic, and combined data to identify rapidly progressive patients was demonstrated, and reference values for clinical trials were provided. Our data indicate that differences in kidney growth rates before adulthood significantly define patients with severe disease. FUNDING: NIDDK grants: Mayo DK058816 and DK090728; CRISP DK056943, DK056956, DK056957, and DK056961; and HALT PKD DK062410, DK062408, DK062402, DK082230, DK062411, and DK062401.

1 January 2010 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
KBKyongtae T. Bae
Kyongtae T. Bae